Trial Profile
The Efficacy and Safety of Aracmyn [Antivenin Latrodectus (Black Widow)Equine Immune F(ab)2], in Patients With Systemic Latrodectism: A Phase II, Multi-Center, Randomized, Double-Blind Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2016
Price :
$35
*
At a glance
- Drugs Antivenin Latrodectus (Primary)
- Indications Spider venom poisoning
- Focus Therapeutic Use
- 20 Oct 2015 New trial record